Fulcrum director sells 18,000 shares in 10b5-1 trade
Fulcrum Therapeutics director Alan Ezekowitz reported an open-market sale of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Fulcrum Therapeutics director Alan Ezekowitz reported an open-market sale of common stock. He sold 18,000 shares of Fulcrum Therapeutics, Inc. at a weighted average price of $3.6452 per share, executed as multiple trades within a disclosed price range.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. Following this sale, Ezekowitz directly holds 10,927 shares of Fulcrum Therapeutics common stock.
Insider Trade Summary
Net Seller: 18,000 shares
Net Sell
1 txn
Insider
Ezekowitz Alan
Role
Director
Sold
18,000 shs ($66K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 18,000 | $3.6452 | $66K |
Holdings After Transaction:
Common Stock — 10,927 shares (Direct)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Key Figures
Shares sold: 18,000 shares
Weighted average sale price: $3.6452 per share
Aggregate sale value (approx.): $65,600
+3 more
6 metrics
Shares sold
18,000 shares
Common Stock sold on June 26, 2026
Weighted average sale price
$3.6452 per share
Open-market sale of Fulcrum Therapeutics common stock
Aggregate sale value (approx.)
$65,600
18,000 shares at $3.6452 weighted average price
Shares owned after transaction
10,927 shares
Direct holdings following June 26, 2026 sale
Net buy/sell shares
-18,000 shares
Form 4 transaction summary shows net-sell direction
Sale price range
$3.555–$3.82 per share
Multiple transactions within this range, forming weighted average
Key Terms
Rule 10b5-1 trading plan, weighted average price, open-market sale, Common Stock
4 terms
Rule 10b5-1 trading plan financial
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale","transaction_code_description": "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
""security_title": "Common Stock","transaction_date": "2026-06-26T00:00:00.000Z""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Fulcrum Therapeutics (FULC) disclose for Alan Ezekowitz?
Fulcrum Therapeutics disclosed that director Alan Ezekowitz sold 18,000 shares of common stock. The Form 4 shows an open-market sale at a weighted average price of $3.6452 per share, leaving him with 10,927 shares held directly after the transaction.
Was the Fulcrum Therapeutics (FULC) insider sale made under a Rule 10b5-1 plan?
Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan. The trading plan was adopted by the reporting person on March 27, 2026, indicating the transactions were pre-arranged rather than discretionary same-day trading decisions.
What does the price range disclosure mean in the Fulcrum Therapeutics (FULC) Form 4?
The filing notes that the reported sale price is a weighted average over multiple trades. Shares were sold between $3.555 and $3.82 per share, and the insider offers to provide detailed trade-by-trade pricing information to the company, security holders, or SEC staff on request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates